patients in Scotland with Type 2 diabetes will now have access to a drug already available in England and Wales.
Studies showed Forxiga (dapagliflozin) helped patients avoid the weight gain associated with insulin use.
The drug has now been approved for patients by the Scottish Medicines Consortium.
Dr David McGrane, consultant physician in diabetes and endocrinology at the Southern General Hospital, Glasgow, said: "Adding dapagliflozin to their insulin regime could help them achieve their blood sugar targets, while also providing a secondary benefit of weight loss."
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article